Designs medical devices and implants for peripheral vascular disease treatment. Markets and sells these devices globally through a direct sales force and distributors. Now — the numbers.
This is an established company with proven profits.
Average growth of 13% a year over the last 4 years. Every year shown ended in profit.
The market pays 31.9× for every dollar of annual profit — around what a business like this usually costs.
Against companies in its own sector, it looks cheaper than 50% of them.
Analysts' average target sits 43% above today's price.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Debt is low and cash is strong; the finances stand solid.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Sales are growing strongly for its sector.
Clearly below the class average.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
The stock trades 31% below its peak. The market has trimmed its expectations for the company.
The net profit margin is 23% — still a thick cushion, though costs have been eating into it lately.
Over the last 4 years, sales grew about 13% a year on average.
There is $359.1M in the vault; even if every debt were paid off, $173.5M would remain.
Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 36/100. For a turnaround signal, the stock first needs to close the gap with the market.
On our five-subject report card, LMAT sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: LMAT is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s what that quality should cost.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (50/100) says the stock isn’t cheap.
Not covered, because the filings we hold do not carry it: the revenue breakdown.